Last reviewed · How we verify
Control Quadrivalent influenza virus vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against four strains of influenza virus.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against four strains of influenza virus. Used for Prevention of influenza caused by influenza A and B viruses in adults and children.
At a glance
| Generic name | Control Quadrivalent influenza virus vaccine |
|---|---|
| Also known as | Vaxigrip Tetra-QIV |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated quadrivalent influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent inactivated influenza vaccine contains antigens from four influenza virus strains (two A subtypes and two B lineages) that trigger both humoral and cell-mediated immune responses. Upon vaccination, the immune system recognizes these viral antigens and generates protective antibodies and memory T cells that provide immunity against infection by these circulating influenza strains.
Approved indications
- Prevention of influenza caused by influenza A and B viruses in adults and children
Common side effects
- Injection site pain, erythema, or swelling
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: